This is an exploratory clinical study evaluating the safety and initial efficacy of BGT007H injection in the treatment of recurrent/metastatic/refractory digestive system tumors.
Voluntarily sign a written informed consent;
Age ≥18 years old, ≤70 years old, male and female;
Expected survival ≥ 3 months;
The Eastern Cancer Collaboration (ECOG) physical fitness score was 0-1;
Active central nervous system metastases (except those stable after treatment);
HIV positive, HBsAg positive, HBV DNA copy number positive (quantitative detection ≥1000cps/ml), HCV antibody positive and HCV RNA positive;
Patients with mental or mental illness who cannot cooperate with treatment and efficacy evaluation;
Subjects with severe autoimmune diseases and long-term use of immunosuppressants;
The Affiliated Hospital of Xuzhou Medical University
Lead sponsor
Guangzhou Bioresette Biomedical Technology Co., Ltd.
Collaborator